MECOM and ovarian cancer: Following on from the above observations, the responses of three RCC cell lines (ccRCC: 786-O and A498; and papillary RCC: ACHN) to everolimus upon ectopic overexpression of full-length EVI1 or EVI1Del190–515—two isoforms identified as oncogenic in ovarian cancer [15]—were assessed.